Baxter International and Merrimack Pharmaceuticals entered an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), an investigational drug in Phase III development for the treatment of metastatic pancreatic cancer in patients previously treated with a gemcitabine-based therapy. Baxter will have exclusive commercialization rights for all potential indications of MM-398 outside the U.S. and Taiwan, and Merrimack ret...